GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. Its share price is dependent on sales success, regulatory approvals in China, and partnerships with Western companies.
Share prices of companies in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company commercializing oncology drugs in the Chinese market. We've categorized it as a "Blood Cancer" company. The chart below shows how investors value companies bringing Western drugs to major Asian markets.
Broad Market Index - GURU.Markets
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. Its unique business model makes it a component of the GURU.Markets index. The chart below shows how its stock, which is heavily exposed to the Chinese market, compares to the US market.
Change in the price of a company, segment, and market as a whole per day
CASI - Daily change in the company's share price CASI Pharmaceuticals
The daily price change of CASI Pharmaceuticals, Inc. reflects the high volatility inherent in biotech companies. The indicator demonstrates sensitivity to sales of its oncology drugs in China and news about clinical trials.
Daily change in the price of a set of shares in a market segment - Cancer blood
CASI Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's high volatility. Comparing this to CASI's performance, which focuses on the Chinese market, helps assess its unique regulatory and commercial risks.
Daily change in the price of a broad market stock, index - GURU.Markets
CASI Pharmaceuticals is a biotech company focused on bringing cancer treatments to the Chinese market. Its business model straddles the intersection of biotech and the specifics of the Chinese market. Its stock price reflects both scientific and geopolitical risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CASI Pharmaceuticals
CASI Pharmaceuticals' year-over-year performance tells the story of its unique business model. Its market capitalization over the past 12 months reflects its success in commercializing imported oncology drugs in the Chinese market, as well as progress in developing its own drug portfolio, which underpins its dual-growth strategy.
Annual dynamics of market capitalization of the market segment - Cancer blood
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on commercializing oncology drugs in the Chinese market. This chart illustrates how its unique strategy, dependence on China's regulatory environment, and sales success impact its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CASI Pharma is a biopharmaceutical company whose stock performance is driven by sales success of its drugs and progress in research, primarily in the Chinese market. The company's business is independent of economic cycles. The chart reflects biotech developments, adjusted for China risks.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on the Chinese market. Its monthly performance reflects both sales of its already approved drugs and progress in clinical programs. Regulatory decisions in China and quarterly revenue reports are key.
Monthly dynamics of market capitalization of the market segment - Cancer blood
CASI Pharmaceuticals focuses on the launch and commercialization of oncology drugs in China. Its business model bridges the gap between Western developments and the vast Chinese market. While the pharmaceutical sector's dynamics mirror global trends, for CASI, the regulatory environment and healthcare system in China are key factors in determining its success.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on commercializing oncology drugs in the Chinese market. Its future depends on sales success and the regulatory environment in China. The broad market (US/global) chart provides a contrasting backdrop to illustrate how its unique China-focused strategy has impacted its performance.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing drugs in the Chinese market. Weekly stock performance depends on sales volumes of its drugs in China, decisions by Chinese regulators, and news of new product additions to its portfolio.
Weekly dynamics of market capitalization of the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing drugs in the Chinese market. Weekly stock performance depends on sales volumes of its drugs in China, decisions by Chinese regulators, and news of new product additions to its portfolio.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CASI, as a biopharmaceutical company focused on China, has a weak correlation with the US market. Comparing its weekly performance with the S&P 500 reveals this diversification effect. The chart shows how Chinese regulatory decisions have a stronger impact on stock prices than global macroeconomic data.
Market capitalization of the company, segment and market as a whole
CASI - Market capitalization of the company CASI Pharmaceuticals
CASI Pharmaceuticals' market capitalization tells the story of a biotech company focused on bringing oncology drugs to the Chinese market. Its chart reflects both the potential of China's vast market and all the risks associated with the regulatory environment and drug commercialization in the country.
CASI - Share of the company's market capitalization CASI Pharmaceuticals within the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. Its market capitalization reflects its unique business model. The chart below shows how investors evaluate its pipeline and its ability to operate in the Chinese market.
Market capitalization of the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on introducing oncology drugs to the Chinese market. The chart below shows the total market capitalization of the blood cancer sector. It illustrates a business model based on licensing and commercializing drugs in one of the world's largest markets.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart illustrates the bridge between American and Chinese pharmaceuticals. CASI Pharmaceuticals licenses and markets Western-developed drugs in China. Its pipeline reflects both the enormous potential of the Chinese market and all the regulatory and geopolitical risks involved.
Book value capitalization of the company, segment and market as a whole
CASI - Book value capitalization of the company CASI Pharmaceuticals
CASI Pharmaceuticals' capital is its portfolio of oncology drugs, both those currently marketed in China and those in development. Its book value reflects this commercial and research capital. The chart below shows how the company, which focuses on the Chinese market, manages its capital while licensing and developing cancer drugs.
CASI - Share of the company's book capitalization CASI Pharmaceuticals within the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company commercializing drugs in China. Its assets include marketing and distribution infrastructure. The chart shows how its physical presence relates to its business model.
Market segment balance sheet capitalization - Cancer blood
Commercialization of oncology drugs, as the BCap_Ges chart for pharmaceuticals shows, requires significant investment not only in R&D but also in marketing and distribution. CASI Pharmaceuticals operates in this environment, balancing science with the creation of a commercial infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
CASI Pharmaceuticals' assets include not only R&D but also the commercial infrastructure for selling oncology drugs in China. The book value reflects both intangible assets and a very real distribution network and drug inventory with tangible manifestations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CASI Pharmaceuticals
CASI Pharmaceuticals is a pharmaceutical company focused on the Chinese market. Its market capitalization is a measure of its drug portfolio and its ability to successfully navigate China's complex regulatory environment. The MvsBCap chart will reflect both clinical success and the specific risks associated with doing business in China.
Market to book capitalization ratio in a market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on oncology, with a market presence in China. Its value depends on the success of its drugs in this vast market. The chart shows how the market values its portfolio and commercial strategy.
Market to book capitalization ratio for the market as a whole
CASI Pharmaceuticals specializes in bringing oncology drugs to the Chinese market. Its business model combines R&D and commercial expertise in one of the world's largest pharmaceutical markets. The company's valuation reflects both its drug portfolio and the risks associated with operating in China.
Debts of the company, segment and market as a whole
CASI - Company debts CASI Pharmaceuticals
CASI Pharmaceuticals, a company commercializing oncology drugs in China, uses capital to license new drugs, conduct local clinical trials, and build its commercial infrastructure. This chart shows how the company finances its unique business model, serving as a bridge between Western innovation and the vast Chinese market.
Market segment debts - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. Bringing drugs to a large but niche market like China requires investment in marketing, distribution, and regulatory processes. The chart shows how the company is funding its expansion in China.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CASI Pharmaceuticals
CASI Pharmaceuticals specializes in bringing cancer drugs to market, often through license acquisitions. This chart shows how the company uses debt to finance these deals and commercialization. High debt creates pressure, requiring rapid sales growth to cover both licensing fees and loan interest.
Market segment debt to market segment book capitalization - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. The chart shows the sector's leverage. It helps assess how the company's unique business model, focused on a specific geographic market, impacts its financial structure.
Debt to book value of all companies in the market
CASI Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of blood cancers. This chart, showing overall capital availability, is critical for biopharma. Funding clinical trials and bringing new oncology drugs to market requires significant investments, which depend on the health of the market.
P/E of the company, segment and market as a whole
P/E - CASI Pharmaceuticals
This chart from CASI Pharmaceuticals, a company commercializing oncology drugs in China, shows the market's appreciation of its unique business model. The dynamics reflect expectations for its drug sales in the vast Chinese market and its ability to introduce new drugs from Western partners.
P/E of the market segment - Cancer blood
This chart shows the average P/E ratio for the pharmaceutical industry where CASI Pharmaceuticals operates in China. This metric helps understand how the market values CASI's unique business model for commercializing Western drugs in the Chinese market compared to other pharmaceutical companies.
P/E of the market as a whole
CASI Pharmaceuticals is a biopharmaceutical company that commercializes cancer drugs developed abroad in China. The company's business model is based on licensing and selling drugs in the Chinese market. This chart shows the biotech sentiment. It helps understand how the market views this strategy and the risks (pricing, regulatory) associated with operating in the Chinese pharmaceutical market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in the Chinese market. Its success depends on drug approvals and sales in the country. This chart shows analyst expectations for the growth of the Chinese pharmaceutical market and the success of CASI's drug portfolio.
%20P%2FE%20CASI%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CASI-Pharmaceuticals&v=1772584613581 "Chart of the company's future (projected) P/E CASI Pharmaceuticals")
Future (projected) P/E of the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for the Chinese market. This chart shows how its future revenue expectations compare to the industry average, reflecting its unique "bridge" business model and potential in the vast Chinese pharmaceutical market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772584613597 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
CASI Pharmaceuticals is a biopharmaceutical company focused on the Chinese market. It commercializes cancer treatments. Its success depends on both the regulatory environment in China and overall investor sentiment toward emerging markets. This chart, reflecting global risk appetite, influences the valuation of such companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772584613621 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on bringing Western oncology drugs to the Chinese market. The company's profitability depends on the successful commercialization of its drug portfolio. This chart shows how the company is leveraging the opportunities of the vast and rapidly growing Chinese pharmaceutical market to build a profitable business.
Profit of companies in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in the Chinese market. Its model is to license promising drugs and bring them to the Chinese market. This chart reflects the rapid growth of the Chinese pharmaceutical market, which creates enormous opportunities for companies capable of establishing distribution and sales.
Overall market profit
CASI Pharmaceuticals specializes in bringing Western oncology drugs to the Chinese market. Its success depends on regulatory approvals and the growth of the Chinese healthcare market. This chart, in the context of the Chinese economy, reflects rising prosperity, which is driving demand for modern medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on bringing innovative oncology drugs developed in the West to the Chinese market. Its business model is to serve as a bridge between markets. This chart reflects analysts' expectations for the growth of the Chinese pharmaceutical market and the success of the company's drug portfolio.
%20profit%20of%20the%20company%20CASI%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CASI-Pharmaceuticals&v=1772584613786 "Graph of future (projected) profit of the company CASI Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for the Chinese market. The company brings both innovative and proven drugs to the Chinese market. This chart shows profitability forecasts for the pharmaceutical sector, helping to evaluate the effectiveness of its business model targeting one of the world's largest markets.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772584613811 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
CASI Pharmaceuticals specializes in commercializing oncology drugs in the Chinese market. Its success depends on regulatory approvals and the Chinese healthcare system. The global corporate earnings forecast presented in the chart provides macroeconomic context for the development of the Chinese economy and its pharmaceutical market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772584613856 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CASI Pharmaceuticals
CASI Pharmaceuticals specializes in oncology drugs for the Chinese market. This chart shows how the market views its sales and strategy. The ratio reflects both the commercial success of its drugs and the enormous potential of the Chinese pharmaceutical market.
P/S market segment - Cancer blood
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing oncology treatments in the United States and China. This chart shows the average revenue estimate for the biotech sector. It helps understand how investors view CASI's pipeline and its strategy in the world's two largest pharmaceutical markets.
P/S of the market as a whole
CASI Pharmaceuticals is a biopharmaceutical company that specializes in commercializing oncology drugs in the Chinese market by licensing them from Western companies. Their business model is a bridge to the Chinese market. This chart helps understand how investors assess the potential and risks of China's pharmaceutical sector through the lens of CASI's business model.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for the Chinese market. Its estimated future sales, shown in this chart, depend on the success of its drugs in China and its ability to expand its portfolio through new licensing agreements.
%20P%2FS%20CASI%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CASI-Pharmaceuticals&v=1772584614040 "The graph of the company's future (projected) P/S CASI Pharmaceuticals")
Future (projected) P/S of the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing drugs in China. Its business model is focused on exploiting the potential of the Chinese pharmaceutical market. This chart shows how investors view its strategy for operating in the Chinese market.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772584614083 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
CASI Pharmaceuticals is a biopharmaceutical company specializing in the Chinese market for blood cancer treatments. This chart, reflecting expectations for rising healthcare costs in China, is key for CASI. The country's economic growth allows for increased healthcare budgets and makes modern oncology drugs more accessible to patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772584614118 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing oncology drugs in China. This chart shows revenue from sales of drugs for which it acquired rights from Western partners. The growth here reflects the growing demand for advanced cancer drugs in the vast Chinese market.
Sales of companies in the market segment - Cancer blood
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing oncology drugs in China. Its business is segmented by individual drugs, both approved and in development. This chart shows revenue from one of its key products in China.
Overall market sales
CASI Pharmaceuticals is a biopharmaceutical company specializing in bringing oncology drugs to the Chinese market. Its business model is based on the growing demand for advanced medicines in China. The company's success reflects both the globalization of the pharmaceutical market and rising healthcare costs in the world's second-largest economy, a powerful trend.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing medicines for the Chinese market. Its sales forecast is dependent on the success of its oncology and hematology drugs in the Chinese market, reflecting the growing demand for innovative medicines in China.
%20sales%20of%20the%20company%20CASI%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CASI-Pharmaceuticals&v=1772584614445 "Schedule of future (projected) sales of the company CASI Pharmaceuticals")
Future (projected) sales of companies in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology drugs in the Chinese market. This chart shows expectations for the blood cancer sector. It helps assess the growth of the oncology drug market in China and the demand analysts predict for innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772584614799 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
CASI Pharmaceuticals specializes in introducing oncology drugs to the Chinese market. Its success depends on the growth of the Chinese healthcare market. This chart of overall sales forecasts, reflecting global trends, indirectly indicates economic prosperity, allowing the country to increase healthcare spending.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772584614841 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CASI Pharmaceuticals
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer drugs in the Chinese market. This chart shows its financial trajectory, where revenue from approved drugs is balanced against clinical trial costs for new candidates, resulting in overall profitability.
Market segment marginality - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company specializing in the commercialization and launch of oncology drugs in China. Their success stems from their ability to navigate the Chinese regulatory system and build sales. The chart shows how profitable their business model is compared to R&D-focused companies.
Market marginality as a whole
CASI Pharmaceuticals is a biopharmaceutical company focused on bringing innovative cancer drugs to the Chinese market. Its business model combines in-house development and licensing. This chart reflects overall profitability, but for CASI, China's vast and rapidly growing pharmaceutical market offers unique growth opportunities.
Employees in the company, segment and market as a whole
Number of employees in the company CASI Pharmaceuticals
CASI Pharmaceuticals operates using a "bridge" model, bringing Western drugs to the Chinese market. This chart shows its team of clinical research, regulatory, and commercialization specialists in China. The team's growth reflects its success in licensing and marketing drugs.
Share of the company's employees CASI Pharmaceuticals within the market segment - Cancer blood
CASI Pharmaceuticals specializes in the launch and commercialization of oncology drugs in China. This business requires a large sales, marketing, and clinical research team. This figure reflects its growing role as an employer in China's vast and rapidly growing pharmaceutical market.
Number of employees in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company specializing in the commercialization of oncology drugs in China. This chart reflects employment in the blood cancer sector. The growing number of oncologists and sales professionals in China indicates the rapid growth of this market and the need for access to modern medicines, which is the foundation of CASI's business model.
Number of employees in the market as a whole
CASI Pharmaceuticals is commercializing oncology drugs in China. Its success depends on regulatory approvals and the country's healthcare system. This chart reflects the situation in the US, but for CASI, the key factors are economic and demographic trends in the Chinese market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the Chinese market. The high market capitalization per employee in this chart may reflect the cost of drug licenses and the potential of the vast Chinese market, rather than the company's large in-house R&D staff, which is typical of this business model.
%20of%20the%20company%20CASI%20Pharmaceuticals%20(CASI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CASI-Pharmaceuticals-CASI&v=1772584615063 "Chart of market capitalization per employee (in thousands of dollars) of the company CASI Pharmaceuticals (CASI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company specializing in the acquisition, development, and commercialization of drugs in China. This indicator reflects the effectiveness of their business model, which combines R&D and commercial expertise in one of the world's largest pharmaceutical markets.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772584615184 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
CASI Pharmaceuticals is a biopharmaceutical company focused on introducing oncology drugs to the Chinese market. Their model is licensing and commercialization. The chart reflects how the market perceives their ability to operate in China's vast but complex pharmaceutical market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772584615225 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals is a biopharmaceutical company focused on licensing, developing, and commercializing Western drugs (primarily cancer) for the Chinese market. This chart demonstrates the effectiveness of their "bridge between markets" business model. It measures how their team in China sells approved drugs, generating profit per employee.
%20Chart%20CASI%20Pharmaceuticals%20(CASI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CASI-Pharmaceuticals-CASI&v=1772584615275 "Company Profit Per Employee (in thousands of dollars) Chart CASI Pharmaceuticals (CASI)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on the commercialization and launch of oncology drugs in China. Their business model is focused on sales and marketing rather than development. This chart shows how effectively their commercial team generates revenue from the sale of licensed drugs in the vast Chinese market.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772584615284 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
CASI Pharmaceuticals (CASI) is a biotech company focused on drug commercialization (primarily oncology) in China. It operates a hybrid model of R&D and sales. This metric reflects how successfully their sales team in China promotes drugs to cover R&D and administration costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772584615327 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology drugs in the Chinese market. This chart reflects the success of its business model. The growth in revenue per employee demonstrates how effectively the company is marketing its drugs in China.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CASI-Pharmaceuticals-CASI&v=1772584615417 "Sales chart per company employee CASI Pharmaceuticals (CASI)")
Sales per employee in the market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on bringing cancer treatments (both Western and domestic) to the Chinese market. This chart compares CASI's revenue per employee to the industry average. This demonstrates the effectiveness of their US-China bridge business model.
Sales per employee for the market as a whole
CASI Pharmaceuticals (CASI) is a biopharmaceutical company operating as a "bridge" between the US and China. They license Western drugs (primarily for blood cancer) for sale in China. They have commercial products. This chart shows how effectively their sales team in China generates revenue.
Short shares by company, segment and market as a whole
Shares shorted by company CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals (CASI) is an American company whose strategy is to license Western drugs (primarily oncology) for sale in China. This model carries dual risks: scientific and regulatory (Beijing's policies). This chart shows the number of investors betting against this risky business model.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CASI-Pharmaceuticals-CASI&v=1772584615483 "Short Shares Chart for the Company CASI Pharmaceuticals (CASI)")
Shares shorted by market segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company that licenses and markets Western-developed cancer drugs in China. This chart shows the betting against the "Chinese biotech" sector. It reflects investor concerns about pricing pressure from the Chinese government and intense competition.
Shares shorted by the overall market
CASI Pharmaceuticals is a biotech company attempting to commercialize cancer drugs in China. This chart illustrates the overall market pessimism. Investors see both scientific risk (R&D) and geopolitical risk (China). During times of fear, this combination of risks causes investors to flee the asset.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CASI Pharmaceuticals (CASI)
CASI Pharmaceuticals is a biotech company that licenses Western drugs (primarily for blood cancer) for sale in the Chinese market. Their success depends on Chinese regulatory approvals and sales. This indicator shows when investors are "overbuying" (above 70) the stock on good news from China or "overselling" (below 30) due to regulatory risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CASI-Pharmaceuticals-CASI&v=1772584615591 "RSI 14 indicator chart for the company's stock CASI Pharmaceuticals (CASI)")
RSI 14 Market Segment - Cancer blood
CASI Pharmaceuticals is a biopharmaceutical company focused on the Chinese market (import and licensing) of drugs for the treatment of blood cancers and other oncological diseases. This chart shows the overall sentiment in the oncology biotech sector. It helps us understand whether CASI's momentum is driven by its success in China or is a general "wave" across the industry.
RSI 14 for the overall market
CASI Pharma, a Chinese biotech company, sees a dual risk in this chart. During periods of euphoria, investors are willing to fund both risky research and investments in emerging markets. During moments of panic, capital flees both biotech and Chinese assets, creating a perfect storm for the company.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CASI (CASI Pharmaceuticals)
CASI Pharmaceuticals (CASI) is a biopharmaceutical company whose business model is to license and commercialize Western drugs (primarily for the treatment of blood cancer) in the Chinese market. This chart shows the average target price from analysts assessing its portfolio and regulatory risks in China.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CASI-CASI-Pharmaceuticals&v=1772584615673 "A chart showing analyst consensus forecasts for the expected stock price. CASI (CASI Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CASI (CASI Pharmaceuticals)
CASI Pharmaceuticals is a biopharmaceutical company with a unique model: it licenses drugs (primarily for cancer) in the West and brings them to the Chinese market. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this "cross-border" strategy and the Chinese market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CASI-CASI-Pharmaceuticals&v=1772584615695 "A chart showing the difference between the consensus forecast and the actual stock price. CASI (CASI Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
CASI Pharmaceuticals (CASI) is a biopharmaceutical company that bridges the gap between China and the US. It licenses and markets US-approved oncology drugs in China. This chart shows general expectations for the blood cancer sector, reflecting experts' belief in growth in the Chinese pharmaceutical market.
Analysts' consensus forecast for the overall market share price
CASI Pharmaceuticals (CASI) is a "bridge" between the US and China. This biopharmaceutical company licenses Western drugs (primarily for blood cancer) and sells them in the Chinese market. This chart shows the overall risk appetite, reflecting investors' willingness to invest in companies dependent on China's complex regulations and economy.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CASI Pharmaceuticals
CASI Pharmaceuticals is a bridge for drugs into China. They don't have R&D from scratch; their business model is licensing (purchasing the rights) to promising Western oncology drugs and commercializing (selling) them in the vast Chinese market. This chart is a summary indicator of their licensing model. It reflects their sales success in China and the high regulatory risks of that market.
AKIMA Market Segment Index - Cancer blood
CASI Pharmaceuticals (CASI) is a biopharmaceutical company whose business model bridges the gap between the US and China. They license Western drugs (primarily for blood cancer) and commercialize them in the Chinese market. The chart shows the average index for the segment, helping investors assess how successful this licensing strategy is compared to the average.
The AKIM Index for the overall market
CASI Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies (hematology) in China. This chart, reflecting the market average, provides a macro backdrop. It helps assess how CASI, a bridge for Western drugs into China, compares to overall economic trends.
